Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism
Status:
Not yet recruiting
Trial end date:
2023-12-06
Target enrollment:
Participant gender:
Summary
The goal of this pilot, open-label prospective study is to evaluate if the effect of calcium
channel blockade on plasma aldosterone levels in people with primary aldosteronism (PA) is
due primarily to Cav1.3 blockade.
This will be tested by treating participants who have PA with both cinnarizine (Cav1.3
blocker) and nifedipine (Cav1.2 blocker) and evaluating effect on aldosterone levels and
blood pressure over a two week course of treatment.